Velocity Clinical Research, Inc.的动态

ACRO's annual meeting was a great opportunity to reflect on the contributions that the clinical research and technology member companies of ACRO have made to advancing the development and delivery of new therapies for patients around the world in 2024. A highlight of the meeting was a video interview between ACRO Board Chair Peyton Howell and FDA Commissioner Dr. Robert Califf reflecting on the agency's efforts to streamline regulatory processes and drive clinical trial innovation. ? Dr. Califf's call to action for clinical research: ?? Rethink global trial distribution ?? Improve rare disease study methods ?? Develop robust data models for real-world evidence ?? Engage in potential FDA reforms. ? #ACRO #FDA Learn more about ACRO's 2024 activities: https://lnkd.in/gZm2vasr

?? Breaking Barriers in Rare Disease Research - From development planning to regulatory submissions, ERGOMED partners with you to design and execute innovative, patient-centric clinical research programs for patients and families living with the challenge of a rare disease. Ready to learn more? Meet our team at Booth #437 at World Orphan Drug Congress USA 2024 next week! Together, let's make a difference. #RareDisease #PatientCentricity #Innovation #ClinicalResearch

Register below to learn more about the emerging important role of methylation-based ctDNA testing applications in MRD and response monitoring!

?? As your clinical trials grow, so do regulatory, resource, and time pressures that can prevent you from scaling efficiently. Our webinar featuring Nicole Latimer and Roche Diagnostics' Khone Saysana and Walter S. dives into strategic eClinical solutions that can help you scale with ease.? Watch it on-demand today: https://bit.ly/45NQJS2

Watch a sneak peek into this #ACRP2024 session where Heidi Kirkpatrick from Merck will guide attendees through the critical elements for a successful clinical trial. Uncover strategies to mitigate deviations, minimize queries, and, ideally, avoid violations altogether. Plan to attend in Anaheim > https://bit.ly/4aOqpJb #GoForIt #GoForEducation #ClinicalTrials #ClinicalResearch #ClinicalResearchStudy #SiteManagement #OncologyTrial

Today on #WorldAlzheimersDay, C-Path honors those affected by Alzheimer’s and reaffirms our commitment to advancing research and drug development. Founded in 2008, the Critical Path for Alzheimer’s Disease is a global, neutral convener, bringing together diverse stakeholders across industry, regulatory agencies, and academia within a pre-competitive forum. By leveraging patient-level data contributions, CPAD enhances regulatory decision-making tools, addresses critical unmet needs, and accelerates therapeutic innovation to improve the lives of those living with Alzheimer’s and related dementias. We are also proud to share that Diane Stephenson, Executive Director of CPAD, will co-chair the “Advancing Regulatory Science to Deliver Precision Medicines” panel at the 2024 NIH Alzheimer’s Summit next week. This important discussion will bring together experts from the FDA to explore how regulatory science can help deliver precision treatments for Alzheimer’s patients. Learn more about CPAD, here: https://lnkd.in/gZjPjKin #CPath #WorldAlzheimersDay #AlzheimersResearch #CPAD #FDA #PrecisionMedicine #NIHSummit

tiakis Biotech AG Reports Clinical Phase Ib/II Trial Results of Tiprelestat for the Treatment of Hospitalized COVID-19 Patients. Tiprelestat was safe and well tolerated, with initial signs of clinical efficacy. Great news on tiakis′ lead program, Martin Voss, Michael Motz and team! https://lnkd.in/edbxppzA #COVID #COVID19 #hospitalized #clinicalstudy #clinicaldata #tiprelestat

ERGOMED’s Approach to Complex Clinical Trial Management. Navigating a complex and challenging study protocol, along with stringent timelines, requires the adoption of a structured, high-quality, yet flexible proactive approach. Download the Case Study: https://lnkd.in/er6xeaVh #Ergomed #OncologyCRO #ClinicalResearchServices #ComplexTrials

?? I am excited to share the Global Genes new report, developed with the Global Genes Corporate Alliance. This is a comprehensive overview highlighting how patient engagement improves clinical trial feasibility, reduces costs, and accelerates timelines.? https://lnkd.in/eZ5X9Vv9 Key Insights from the Report: Elevating Feasibility:?Engaging patient communities early provides critical insights that reduce enrollment delays and the need for costly protocol amendments, help identify key trial sites, and more. Qualitative Insights Matter:?Understanding the patient experience uncovers barriers, helping drug developers design trials that truly work for rare disease populations. Accelerating Therapies:?Engaging patients early reduces costly delays by improving enrollment and retention, allowing drug developers to get their products to market faster. Breaking Down Barriers:?By understanding the demands on patients and caregivers, trials can address logistical and procedural challenges that deter participation. Building Trust:?Transparent collaboration between industry and patient communities fosters trust, ensuring trials align with patient needs and priorities. This report underscores a powerful message: The patient community is a source of under-utilized expertise that can better inform discovery and development of rare disease therapies. Thank you Gianluca Pirozzi contributing your insights! Charlene Son Rigby Nicole Boice Daniel Levine #EarlyAndOften #GlobalGenes #ClinicalTrialFeasibility #CareAboutRare

New on the Blog: Preparing for FDA-Mandated Diversity Action Plans (DAPs) in Clinical Trials As the FDA moves to ensure clinical trials better reflect diverse patient populations, sponsors face new requirements and opportunities for inclusive research. In our latest post, Suzanne Harris explains what you must know about preparing for DAPs to meet FDA expectations. Learn more: https://lnkd.in/e2QzAaNH